Kapağı yeniden konumlandırmak için sürükleyin
@sheetbabies00
Hakkında
A new randomized stage The second research evaluating the actual usefulness along with security with the glyco-optimized anti-EGFR antibody tomuzotuximab in opposition to cetuximab throughout individuals along with frequent and/or metastatic squamous mobile or portable most cancers from the head and neck : the RESGEX study.
Takip ettikleri
(1)
Takipçiler
(1)
Avatarını kırp
